anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Questionnaires and scales will be filled out by the researcher 5 minutes before blood collection. The child will be allowed to play with the liquid moving, timed fountain toy 3 minutes before blood collection. During the process, the child will continue to play with the toy. The scales will be filled again 5 minutes after blood collection.
PURPOSE: To obtain tea of Nelumbo nucifera Gaertn. containing whole grass of Nelumbo nucifera Gaertn. or finely cut material of one or more parts among flower, leaf, stem and subterranean stem of Nelumbo nucifera Gaertn. as an essential component, useful for recovery of fatigue and emaciation, improvement of weak constitution and nourishment and robustness and capable of favorably being taken in by a wide generation. CONSTITUTION: This tar of Nelumbo nucifera Gaertn. contains dried and finely cut material of whole grass or one or more parts among flower, fruit, leaf, stem and subterranean stem, and the whole grass or the above part is dried and finely cut and then roasted at 150-160 deg.C for 5-10min. Thereby, quality of tea can be retained for a long period without impairing taste and active ingredient and nasty smell and bitterness are reduced and favorably taken by a wide generation.
This is an open-label study of an oral formulation of risperidone to be taken daily over 12 months by children and adolescents with conduct and other disruptive behavior disorders. It is an extension of a randomized, double-blind study (RIS-INT-79) comparing risperidone with placebo over 6 months in patients who had already shown response to the medication for a period of 12 weeks. Efficacy assessments include: the Conduct Problem subscale of the Nisonger Child Behavior Rating Form (N-CBRF), a measure of symptoms of conduct and other disruptive behavior disorders; Visual Analogue Scale for the most troublesome symptom (VAS-MS), a scale ranging from not troublesome to extremely troublesome; Clinical Global Impression-Severity of Illness (CGI-Severity), a measure of overall severity of illness; Children's Global Assessment Scale (C-GAS), as assessment overall functioning. Safety evaluations include incidence of adverse events, physical examinations, laboratory tests (biochemistry, hematology, and urinalysis), and electrocardiograms (ECGs). Oral risperidone solution (1milligram/milliliter) daily for 1year. For patients weighing at least 50kg, start dose is 0.5ml/day. At investigator's discretion, dose may be increased (maximum 1.5ml/d over 5 days). Patients under 50kg start at 0.25ml/d, increased, if required, to maximum 0.75ml/d.
Colorectal cancer (CRC) is one of the most common causes of cancer-related deaths. While polyp detection is important for diagnosing CRC, high miss rates for polyps have been reported during colonoscopy. Most deep learning methods extract features from images using convolutional neural networks (CNNs). In recent years, vision transformer (ViT) models have been employed for image processing and have been successful in image segmentation. It is possible to improve image processing by using transformer models that can extract spatial location information, and CNNs that are capable of aggregating local information. Despite this, recent research shows limited effectiveness in increasing data diversity and generalization accuracy. This paper investigates the generalization proficiency of polyp image segmentation based on transformer architecture and proposes a novel approach using two different ViT architectures. This allows the model to learn representations from different perspectives, which can then be combined to create a richer feature representation. Additionally, a more universal and comprehensive dataset has been derived from the datasets presented in the related research, which can be used for improving generalizations. We first evaluated the generalization of our proposed model using three distinct training-testing scenarios. Our experimental results demonstrate that our ColonGen-V1 outperforms other state-of-the-art methods in all scenarios. As a next step, we used the comprehensive dataset for improving the performance of the model against in- and out-of-domain data. The results show that our ColonGen-V2 outperforms state-of-the-art studies by 5.1%, 1.3%, and 1.1% in ETIS-Larib, Kvasir-Seg, and CVC-ColonDB datasets, respectively. The inclusive dataset and the model introduced in this paper are available to the public through this link: https://github.com/javadmozaffari/Polyp_segmentation .
Participants in this group will be counselled by a registered dietician and then undergo a 4-week preoperative well formulated ketogenic diet. They will record all nutritional uptake during the diet using an app called Cronometer and provide weekly summary reports to the study team.
<P>PROBLEM TO BE SOLVED: To provide a new anti-allergic agent obtained by using a readily available natural resource having slight disturbance to a plant individual.  <P>SOLUTION: The anti-allergic agent comprises an extract of Daemonorops draco resin as an active ingredient. The phenol derivative is selected from compounds of figures being products separated from the extract. A preferable extraction solvent is an alcohol, an acetic acid ester, a ketone, an alkane or their mixture. The separation of the compounds is carried out by a silica gel column chromatography (SigelCC).  <P>COPYRIGHT: (C)2010,JPO&INPIT
Tirabrutinib 10 mg capsules orally twice daily (BID) (morning and approximately 12 hours later) for 7 days. On Day 7, only morning dose was administered.
<P>PROBLEM TO BE SOLVED: To provide a means for protecting a dental surface by biomimetically precipitating fluorapatite succeeding to a conventional bleaching treatment.  <P>SOLUTION: A protection agent is used. The protection agent comprises at least one gel film A prepared in advance, comprising at least one gel forming agent A1, water or a mixture A2 comprising water and an organic solvent, phosphate ions or hydrogen phosphate ions A3, a fluoride A4 if needed, at least one amino acid A5 if needed and a carboxylic acid or a buffer system A6 for bringing a pH value to be 4-7 and having 50-1,000 μm thickness if needed, and at least one gel film B prepared in advance, comprising at least one gel forming agent B1, water B2 and calcium ions Ca<SP>2+</SP>B3 and having 50 μm-5 mm thickness. By the invention, embrittlement of teeth caused by bleaching is protected and bleaching effect is retained. Pores and cracks generated by the bleaching is closed by re-calcification, new coloration is reduced and hyperesthesis is relieved.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Epidemiologic studies have shown that gastroenteritis in infants is associated with several viruses, including norovirus, sapovirus and rotavirus. These viruses together or individually can be associated with illness ranging from asymptomatic to serious. Asymptomatic infection can create a reservoir, allowing further spread of the virus, whereas serious illness can lead to death, particularly in the very young, very old or immunocompromised. As the burden of rotavirus in children decreases due to successful rotavirus vaccination programs in infants, norovirus infections are increasingly recognized as the primary cause of acute gastroenteritis (AGE) in many countries around the world. Currently, there is no available vaccine to counter the disease burden associated with norovirus. Vaccinating at an early age would reduce the severe illness in young children and also reduce the asymptomatic cases which act as a vehicle for transmission within the population. As infants already receive multiple vaccines during the first months of life, an additional vaccination must fit into the immunization scheme in a convenient way for compliance. It must also have an acceptable safety profile and be immunogenic without interfering with the immune response to routine childhood vaccines.
ABSTRACT     Periodic bleeding, e.g. fortnightly or weekly, of pregnant mares is carried out with return to the blood stream of the mare all cellular constituents in the withdrawn blood and also the plasma constituents having a molecular weight above about 40,000 m.w.  Optionally, the plasma constituents having a molecular weight below about 20,000 m.w. are returned as well.          The 20,000-40,000 m.w. fraction of the plasma constitutes a Chorionic Gonadotropic Hormone product of high purity.
The invention discloses total panax notoginsenosides, a preparing method thereof, preparations thereof and applications thereof. The total panax notoginsenosides comprise a ginsenoside Rg 1 and a ginsenoside Rb 1, with the weight ratio of the ginsenoside Rg 1 to the ginsenoside Rb 1 being 1:0.9-1.1. The preparing method includes smashing a raw material pseudo-ginseng into coarse powder, adding 8-12 times by weight of ethanol having a concentration of 60-80%, performing reflux extraction for 2-4 times for 1-2 h in each time, performing rough filtration after each extraction step, combining the filtrates of rough filtration, performing refined filtration, concentrating the filtrate of the refined filtration until the specific density is 1.3-1.5, thus obtaining the total panax notoginsenosides. The total panax notoginsenosides can be prepared into granules, capsules, tablets, pills, oral liquids and injections. The applications relate to applications of the total panax notoginsenosides in preparation of medicines used for preventing and/or treating ischemic cerebrovascular disease. The weight ratio of the ginsenoside Rg 1 to the ginsenoside Rb 1 is controlled to be within the range of 1:0.9-1.1. The total panax notoginsenosides can reduce the area of cerebral infarction caused by cerebellar ischemia/reperfusion and can improve neurobehavioral disturbances caused by the cerebral ischemia/reperfusion.
INTRODUCTION: Among the persistent conditions affecting patients in the post-acute COVID-19 period, sarcopenia is increasingly emphasized. In this study, we aimed to determine the incidence of sarcopenia and to reveal the risk factors predicting it in hospitalized survivors of COVID-19.
METHODOLOGY: This is a retrospective cohort study conducted between December 2021 and May 2022 in the post-COVID follow-up center of a tertiary hospital in Turkey. One hundred and sixty-eight patients who were hospitalized because of COVID-19 and discharged were included in the study. The SARC-F scale was applied to determine the risk of sarcopenia in the participants. Twelve patients with a SARC-F score ≥ 4 before COVID-19 were excluded from the study. The medical records of the remaining 156 participants were reviewed, and their demographic characteristics, COVID-19 disease data, hemogram, and CRP parameters were also noted.
RESULTS: Sarcopenia risk was detected in 17 (10.9%) patients whose median age was higher than the others. Increased risk for sarcopenia was higher in women, lack of education, use of assisted respirators at home, having a psychiatric illness, losing > 10% weight during the hospitalization, and being treated in the intensive care unit. Multiple regression analysis showed that female gender (OR: 8.04 [1.51-42.76]), having a psychiatric illness (OR: 13.23 [2.12-82.51]), and losing > 10% weight during hospitalization (OR: 18.46 [2.57-132.72]) predicted the sarcopenia risk.
CONCLUSIONS: Sarcopenia should be closely monitored in patients with cases of severe inflammatory effect, inadequate food intake, and diminished physical activity such as hospitalized survivors of COVID-19.
Refractory rheumatoid arthritis patients who met the inclusion/exclusion criteria have been selected. After signing informed consent form, autologous stem cells were obtained by bone marrow aspiration. Isolation and culture (3 to 4 weeks in MEM-alpha medium) of mesenchymal stem cells (MSCs) were performed in accredited good manufacturing practices (GMP) clean room. A panel of cluster of differentiation (CD) markers including CD105, CD166, CD44, CD45, CD90, and CD34 were checked for making sure about differentiation of cells into MSCs after 3-4 weeks of cell culture. Viability of MSCs was checked by Trypan blue testing and all of the cultivations were negative for bacterial contamination. A single dose of 1000000 to 2000000 mesenchymal stem cells/kg infused into patients intravenously. To prevent anaphylactic reactions, a single intravenous dose of hydrocortison (100 ml) and oral dimenhydrinate (10 ml) were administered before MSCs infusion into patients. The effects of mesenchymal stem cells on the cellular and humoral immune responses and also the role of chemokines in homing of immune cells were studied at time points 1, 6 and 12 months after intravenous administration of MSCs in refractory rheumatoid arthritis.
The invention relates to the field of medicine, in particular to a new purpose of SAMC (S-allylmercaptocysteine). The invention provides application of the SAMC to the inhibition of liver cancer cell activity and inhibition of liver cell invasion or adsorption. Experiments prove that by using the activity of cells not treated by SAMC cells as the control, the relative activity of HepG2 cells treated through 1mmol/L SAMC is less than 60 percent; the relative activity of Huh-7 cells treated by 1mmol/L SAMC is less than 50 percent. The apoptosis rate of HepG2 cells treated by 1mmol/L SAMC is 23 percent, and the apoptosis rate of Huh-7 cells treated by 1mmol/L SAMC is 24 percent. In addition, through the SAMC treatment, the liver cell invasion or adsorption capability is obviously reduced. Therefore the invention provides the application of the SAMC to the preparation of medicine for treating the liver cancer.
Using local anesthetic and strict aseptic precautions, the tip of the 18-20 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 2ml. of local anesthetic ( 1% xylocaine) will be injected into the bursa. The needle tip will be advanced into the supraspinatus tendon and ½ ml or less of 0.5% Sensorcaine will be injected into the pseudo capsule around the calcification. Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudo capsule. During this procedure, or after the fragmentation, using a syringe of saline or local anesthetic( 1% xylocaine) and with pumping action of the syringe the calcification with be sucked into the syringe.
Reactivation of the latent human herpes virus, Cytomegalovirus (CMV), post allogeneic haematopoietic stem cell transplantation (Allo-HSCT) can result in significant morbidity and mortality unless treated promptly. Anti-viral therapy is usually effective, but has serious side effects typically requiring prolonged inpatient admission, such as myelosuppression (Ganciclovir) or nephrotoxicity (Foscarnet). Cellular immunotherapy for CMV has been tested in Phase I/II trials in the UK and Europe. In these trials CMV-specific T cells were isolated from the peripheral blood of CMV seropositive donors and re-infused into recipients following CMV reactivation resulting in sustained anti-viral responses. It is clear that post-transplant recovery of CD8+ CMV-specific cytotoxic T-cells (CTL) abrogates the development of CMV-related disease. An advantage of cellular therapy for CMV reactivation is the transfer of immunological memory, which can reduce the number of subsequent reactivations. This is important, as rapidly increasing numbers of highly immunosuppressive (or T cell depleted) reduced intensity conditioning Allo-HSCTs are being performed in the UK. These approaches reduce the toxicity of transplantation in older patients with more co-morbidities. Reduced intensity allogeneic transplants are currently part of the UK MRC AML15 trial and are to be recommended in the proposed MRC/ECOG UKALL14 study and again in UK MRC AML17. In addition, a number of NCRN approved UK multicentre extended Phase II studies have recently started using reduced intensity Allo-HSCT in various lymphoma subtypes.

Transplant recipients with CMV seronegative donors cannot benefit from currently available cellular immunotherapy approaches due to the lack of CMV-specific memory T cells in these donors. At present, there is no reliable strategy to isolate virus specific T cells from uninfected naïve individuals, as the precursor frequency is low or absent and the in vitro priming of T-cell responses is inefficient. T-cell receptor (TCR) gene transfer offers a strategy to produce antigen-specific T cells independent of precursor frequency and without the need for T-cell priming. As approximately 50% of adult individuals have been previously infected with CMV, there are significant numbers of CMV 'mismatched' Allo-HSCT performed, where the donor is CMV seronegative and the recipient CMV seropositive. The proposed study will test the feasibility of generating donor-derived CMV-specific T cells via the ex vivo introduction of a CMV-specific T cell receptor using a GMP grade retroviral vector.
Human papillomavirus (HPV)-positive Head and Neck Squamous Cell Carcinomas (HNSCC) comprise a particular cancer entity traditionally associated with better clinical outcomes. Around 25% of HNSCC are HPV positive, HPV16 being the most prevalent type. Nevertheless, close to 30% of the HPV-positive patients have an unfavorable prognosis, revealing that this type of tumor exhibits great heterogeneity leading to different clinical behaviors. Efforts have been made to identify RNA molecules with prognostic value associated with the clinical outcome of patients with HPV-positive HNSCC, with the aim of identifying patients at high risk of metastasis, disease recurrence, and poor survival, who would require closer clinical follow-up and timely intervention. Moreover, the molecular identification of those HPV-positive HNSCC patients with good prognosis will allow the implementation of de-escalating therapeutic strategies, aiming to reduce side effects, resulting in a better quality of life. This review compiles a series of recent studies addressing different methodological and conceptual approaches aimed at searching for potential gene expression-based biomarkers associated with the prognosis of patients with HPV-positive HNSCC.
FIELD: chemical-pharmaceutical industry. SUBSTANCE: invention focuses on manufacturing air- or gas-filled microbeads surrounded by polymer wrap made of synthetic polymer and serving to inject or introduce into live organisms orally, rectally, or urethrally for therapeutic or diagnostic aims (echography). Properties of polymer membrane of microbeads (elasticity, permeability, biodegradability) can be regulated by way of choosing polymer, conditions under which deposition onto phase interface occurs, and polymer additives. Condensation of polymer in the suspension ranges from 0.00004 to some 400 mg/ml, thickness of the wrap 50 to 500 nm, and air or gas amount from 0.00003 to some 500 mcl per 1 ml of suspension. Microbeads are manufactured by depositing polymer substance onto phase interface, preparing oil-in-water emulsion, adding polymer insoluble in water phase, precipitating polymer, and removing encapsulated hydrophobic phase, which is evaporated simultaneously with water phase while replacing them by air or gas. EFFECT: facilitated manufacturing procedure. 22 cl
Biomarkers in chronic lymphocytic leukemia (CLL) allow assessment of prognosis. However, the validity of current prognostic biomarkers based on a single assessment point remains unclear for patients who have survived one or more years. Conditional survival (CS) studies that address how prognosis may change over time, especially in prognostic subgroups, are still rare. We performed CS analyses to estimate 5-year survival in 1-year increments, stratified by baseline disease characteristics and known risk factors in two community-based cohorts of CLL patients (Freiburg University Hospital (n = 316) and Augsburg University Hospital (n = 564)) diagnosed between 1984 and 2021. We demonstrate that 5-year CS probability is stable (app. 75%) for the entire CLL patient cohort over 10 years. While age, sex, and stage have no significant impact on CS, patients with high-risk disease features such as non-mutated IGHV, deletion 17p, and high-risk CLL-IPI have a significantly worse prognosis at diagnosis, and 5-year CS steadily decreases with each additional year survived. Our results confirm that CLL patients have a stable survival probability with excess mortality and that the prognosis of high-risk CLL patients declines over time. We infer that CS-based prognostic information is relevant for disease management and counseling of CLL patients.
Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
CPT-C (Cognitive Processing Therapy-cognitive only) is a standardized, manual-based treatment consisting of 12, 60-minute sessions which will be given twice per week. Sessions will focusing on specific issues, learning new therapeutic techniques and setting up homework for the following session including real-life application of learned CPT techniques.
PURPOSE:To obtain a cosmetic having excellent spread, application feeling, applicability and stability with neat feeling without tackiness containing addition product of fatty acid of sugars such as glucosamine or N-acetylglucosamine as oil-gelling agent. CONSTITUTION:The aimed cosmetic contains addition product of fatty acid of sugars selected from glucosamine, N-acetylglucosamine and homopolymer or copolymer of said compounds having <=10 degree of polymerization as oil- gelling agent. A compoud obtained by hydrolysis of chitin and/or chitosan is preferable as sugars. Further, average degree of fatty acid substitution to sugars is preferably 1-3.5. Said cosmetic has excellent spread and neat feeling without tackiness, and excellent application feeling and applicability like as insensible of film thickness to finished film after make-up. Besides, said cosmetic has excellent shape-keeping state, stability and quality and is able to be prepared as product from gel-like to solid-like.
The present invention relates to the complete biosynthetic pathway for the formation of the LL-F28249 compounds and, most importantly, the major component LL-F28249α. The purified and isolated nucleic acid molecule encoding the proteins of the biosynthetic pathway, which is isolated from a wild-type or mutant  Streptomyces , is fully described in FIG.  6  to FIG.  6 - 39 and SEQ ID NO:1. The DNA gene cluster and its expression in a suitable host enable the efficient production of the highly active natural metabolites and semisynthetic derivatives. The invention further concerns plasmids, vectors and host cells that contain and express the novel nucleic acid molecule. Of particular interest, the entire biosynthetic pathway fits compactly in three plasmids, Cos11, Cos36 and Cos40. The invention also concerns the purified and isolated biosynthesis proteins that are encoded by the whole DNA gene cluster. Additionally, the invention involves a new efficient, biochemical method of preparing moxidectin.
The embodiments herein relate to a multi-vitamin kids' gummies composition and a method of making the same. The multi-vitamin kids' gummies comprises a fruit powder, a thickening agent, a vitamin mix and water. The fruit powder is baobab fruit powder. The thickening agent is gelatine. The method of making multi-vitamin kids' gummies comprises mixing a predetermined amount of water and a predetermined amount of a thickening agent to obtain a mixture. The mixture is boiled to get a gel-like consistency. The mixture is cooled to room temperature. A predetermined amount of a fruit powder is added to the mixture. The fruit powder is baobab fruit powder. The mixture is kept at room temperature for at least 15 minutes and the mixture is molded to form gummies or candies.